SECURITIES AND EXCHANGE COMMISSIONSEC FORM 17-C

CURRENT REPORT UNDER SECTION 17
OF THE SECURITIES REGULATION CODE
AND SRC RULE 17.2(c) THEREUNDER

1. Date of Report (Date of earliest event reported)

Nov 8, 2023

2. SEC Identification Number

PW-937

3. BIR Tax Identification No.

000-391-438-000

4. Exact name of issuer as specified in its charter

EEI CORPORATION

5. Province, country or other jurisdiction of incorporation

MANILA, PHILIPPINES

6. Industry Classification Code(SEC Use Only)

7. Address of principal office

NO. 12 MANGGAHAN STREET, BAGUMBAYAN, QUEZON CITY Postal Code 1110

8. Issuer's telephone number, including area code

(+632) 8-334-2677

9. Former name or former address, if changed since last report

The Issuer has not changed its address since its last report to the Honorable Commission.

10. Securities registered pursuant to Sections 8 and 12 of the SRC or Sections 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock Outstanding and Amount of Debt Outstanding
COMMON	1,036,281,485
EEIPA	15,000,000
EEIPB	45,000,000

11. Indicate the item numbers reported herein

N/A

The Exchange does not warrant and holds no responsibility for the veracity of the facts and representations contained in all corporate disclosures, including financial reports. All data contained herein are prepared and submitted by the disclosing party to the Exchange, and are disseminated solely for purposes of information. Any questions on the data contained herein should be addressed directly to the Corporate Information Officer of the disclosing party.

EEI CorporationEEI

PSE Disclosure Form 4-2 - Acquisition/Disposition of Shares of Another Corporation
References: SRC Rule 17 (SEC Form 17-C) and
Section 4.4 of the Revised Disclosure Rules

Subject of the Disclosure
Sale of Issuer's 60% interest in its subsidiary, BiotechJP Corporation
Background/Description of the Disclosure
Today, November 7, 2023, Issuer executed a Deed of Assignment selling all of its interest in its subsidiary, BiotechJP Corporation to Earthman Consulting & Development Corporation.

Date of Approval by Board of Directors	Sep 22, 2023

Rationale for the transaction including the benefits which are expected to be accrued to the Issuer as a result of the transaction
The sale is part of the Issuer's strategy to exit from its non-core business.

Details of the acquisition or disposition

Date	Nov 7, 2023

Manner
Disposition thru payment of cash consideration
Description of the company to be acquired or sold
BiotechJP Corporation, a subsidiary of the Issuer engaged in the business of manufacturing food and therapeutic food.

The terms and conditions of the transaction

Number of shares to be acquired or disposed	181,815
Percentage to the total outstanding shares of the company subject of the transaction	60
Price per share	275.00

Nature and amount of consideration given or received
Consideration is paid in cash in the total amount of PhP50,000,000.00
Principle followed in determining the amount of consideration
The consideration was determined by applying premium to the book value for the Issuer.
Terms of payment
Full payment upon execution
Conditions precedent to closing of the transaction, if any
Subject to the issuance of electronic Certificate Authorizing Registration by the BIR.
Any other salient terms
None

Identity of the person(s) from whom the shares were acquired or to whom they were sold

Name	Nature of any material relationship with the Issuer, their directors/ officers, or any of their affiliates
Earthman Consulting & Development Corporation	None

Effect(s) on the business, financial condition and operations of the Issuer, if any
Upon completion of the sale, the Issuer will have completely divested all its interest in BiotechJP Corporation and will no longer be its subsidiary. Other than this, there is no other effect on the Issuer’s business, financial condition and operations.
Other Relevant Information
Please see attached Amended SEC FORM 17C.